Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma
Open Access
- 1 April 2013
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (4) , 408-414
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation ProfilingMolecular Cancer Therapeutics, 2012
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS SignalingCancer Research, 2010
- MET Receptor Sequence Variants R970C and T992I Lack Transforming CapacityCancer Research, 2010
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 2010
- Ethnic Differences and Functional Analysis of MET Mutations in Lung CancerClinical Cancer Research, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004